Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch’s membrane rupture

Abstract

Choroidal neovascularization (CNV) secondary to traumatic rupture of Bruch's membrane is a rare condition, without standardized treatment. Here we describe one case of CNV related to traumatic rupture of Bruch's membrane which was successfully treated with intravitreal injection of ranibizumab. A 14-year-old patient was referred for ocular contusion, complicating interpapillomacular rupture of Bruch's membrane in left eye. Indeed, a correct initial visual acuity, juxtafoveolar CNV appeared 4 months later on the border of Bruch's membrane rupture. The patient was treated with an off-label intravitreal ranibizumab because of worsening of visual acuity. One month after intravitreal injection, visual acuity improved, from 20/40 to 20/25. At 12-month follow-up, visual acuity remained at 20/25, fundus examination. Fluorescein angiography, indocyanine green angiography and optic coherence tomography showed fibrotic evolution of CNV. The Bruch's membrane rupture remained stable. No side-effect of intravitreal injection of ranibizumab was observed. For this patient affected with CNV secondary to traumatic Bruch's membrane, one single intravitreal ranibizumab injection was efficient, with 1-year follow-up.